Fairfield Bush & CO. boosted its position in shares of Novartis AG (NYSE:NVS) by 5.2% in the fourth quarter, HoldingsChannel reports. The firm owned 99,693 shares of the company’s stock after acquiring an additional 4,916 shares during the period. Novartis makes up about 2.3% of Fairfield Bush & CO.’s investment portfolio, making the stock its 13th largest position. Fairfield Bush & CO.’s holdings in Novartis were worth $8,370,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVS. Wealthcare Advisory Partners LLC bought a new position in Novartis during the 3rd quarter worth about $106,000. Pinnacle Wealth Planning Services Inc. bought a new position in Novartis during the 4th quarter worth about $113,000. Calton & Associates Inc. bought a new position in Novartis during the 4th quarter worth about $118,000. SeaCrest Wealth Management LLC bought a new position in Novartis during the 4th quarter worth about $124,000. Finally, Trustcore Financial Services LLC bought a new position in Novartis during the 4th quarter worth about $178,000. Hedge funds and other institutional investors own 10.76% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of research firms have issued reports on NVS. Nord/LB reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. UBS reiterated a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Finally, Zacks Investment Research cut Novartis from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $87.51.

Novartis AG (NVS) opened at $79.88 on Friday. The firm has a market capitalization of $188,501.86, a PE ratio of 24.58, a PEG ratio of 1.90 and a beta of 0.78. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31. Novartis AG has a 1-year low of $72.67 and a 1-year high of $94.19.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.04. The company had revenue of $12.92 billion during the quarter, compared to analysts’ expectations of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. Novartis’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 EPS. sell-side analysts expect that Novartis AG will post 5.33 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/fairfield-bush-co-grows-holdings-in-novartis-ag-nvs/1959452.html.

Novartis Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.